Ascletis Pharma's (HKG:1672) ASC37 demonstrated superior weight loss to tirzepatide in a diet-induced obese mouse model, according to a Monday Hong Kong bourse filing.
The company will submit an investigational new drug application of both ASC37 once-monthly subcutaneous and oral formulations in the third quarter.
Biologics license applications for the formulation will be submitted to the U.S. Food and Drug Administration after phase III completion.